Literature DB >> 16788573

Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells.

Qi Cao1, Xin Lu, You-Ji Feng.   

Abstract

Although glycogen synthase kinase-3 (GSK-3) might act as a tumor suppressor since its inhibition is expected to mimic the activation of Wnt-signaling pathway, GSK-3beta may contribute to NF-kappaB activation in cancer cells leading to increased cancer cell proliferation and survival. Here we report that GSK-3beta activity was involved in the proliferation of human ovarian cancer cell both in vitro and in vivo. Inhibition of GSK-3 activity by pharmacological inhibitors suppressed proliferation of the ovarian cancer cells. Overexpressing constitutively active form of GSK-3beta induced entry into the S phase, increased cyclin D1 expression and facilitated the proliferation of ovarian cancer cells. Furthermore, GSK-3 inhibition prevented the formation of the tumor in nude mice generated by the inoculation of human ovarian cancer cells. Our findings thus suggest that GSK-3beta activity is important for the proliferation of ovarian cancer cells, implicating this kinase as a potential therapeutic target in ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788573     DOI: 10.1038/sj.cr.7310078

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  80 in total

1.  Negative regulation of HIF-1α by an FBW7-mediated degradation pathway during hypoxia.

Authors:  Jessica M Cassavaugh; Sarah A Hale; Theresa L Wellman; Alan K Howe; Cheung Wong; Karen M Lounsbury
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

Review 2.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 3.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

4.  Delayed administration of a single dose of lithium promotes recovery from AKI.

Authors:  Hui Bao; Yan Ge; Zhen Wang; Shougang Zhuang; Lance Dworkin; Ai Peng; Rujun Gong
Journal:  J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 10.121

5.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

6.  Lithium chloride and inhibition of glycogen synthase kinase 3β as a potential therapy for serous ovarian cancer.

Authors:  Akiva P Novetsky; Dominic M Thompson; Israel Zighelboim; Premal H Thaker; Matthew A Powell; David G Mutch; Paul J Goodfellow
Journal:  Int J Gynecol Cancer       Date:  2013-02       Impact factor: 3.437

Review 7.  Wnt signaling in ovarian tumorigenesis.

Authors:  T A Gatcliffe; B J Monk; K Planutis; R F Holcombe
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

Review 8.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

9.  Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer.

Authors:  Yu Jin Cho; Ji Hun Kim; Jiyeon Yoon; Sung Jin Cho; Young San Ko; Jong-Wan Park; Hye Seung Lee; Hee Eun Lee; Woo Ho Kim; Byung Lan Lee
Journal:  BMC Gastroenterol       Date:  2010-08-12       Impact factor: 3.067

10.  Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.

Authors:  V Bilim; A Ougolkov; K Yuuki; S Naito; H Kawazoe; A Muto; M Oya; D Billadeau; T Motoyama; Y Tomita
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.